Investigating new treatments for acute myeloid leukemia using plant-derived compounds
Official title: Targeting metabolism in AML
Funded at Louis Stokes Cleveland VA Medical Center · NIH-11126522 · Data updated 2026-11-12
This study is looking at a natural compound from plants that might help fight acute myeloid leukemia (AML) by slowing down the growth of cancer cells, and they're testing it in mice to find the best way to help patients like you.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Louis Stokes Cleveland VA Medical Center NIH-funded |
| Lab location | 1 site (Cleveland, United States) |
| Project start | October 1, 2020 |
| Project end | September 30, 2025 |
| Funding year | 2025 |
| NIH project number | 5I01BX004995-05 |
| Project ID | NIH-11126522 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are adults diagnosed with acute myeloid leukemia, particularly those over the age of 56 who have limited treatment options.
✕Less likely to help
Patients with other types of leukemia or those who are not diagnosed with acute myeloid leukemia may not benefit from this research.
What this research studies
This research focuses on developing new therapies for acute myeloid leukemia (AML), a type of cancer that primarily affects adults. The team has identified a plant-derived compound that shows promise in inhibiting the growth of AML cells. They will explore how this compound affects cancer cell metabolism by studying its interaction with a specific enzyme called thioredoxin reductase. The research involves testing various analogues of this compound in mouse models to find the most effective treatment options for patients.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for patients with acute myeloid leukemia, potentially improving survival rates.
How similar studies have gone: Other research has shown promise in targeting cancer metabolism, suggesting that this approach could yield significant advancements in treatment.
Where this research is happening
-
Louis Stokes Cleveland VA Medical Center
Cleveland, United States Active
Researchers
- Principal investigator: Wald, David — Louis Stokes Cleveland VA Medical Center
- Study coordinator: Wald, David
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.